News | July 25, 2012

Technology Allows More Atlanta Patients to Self-Manage Their Heart Disease

Data on how Emmi Solutions’ technology improves patient flow, care and reimbursement to be showcased at AHA’s 2012 Leadership Summit

July 25, 2012 — Grady Memorial Hospital has standardized and improved patient education and reduced by 75 percent the amount of time staff spend educating new patients about warfarin by implementing Emmi Solutions’ interactive multimedia program in its Coumadin clinic. This has allowed Grady, the largest hospital in Georgia and the public hospital for Atlanta, to add 138 patient appointment slots per month to better meet the needs of a growing heart disease population. This study was selected as a poster display at the 20thAnnual Health Forum and the American Hospital Association Leadership Summit to be held July 19 to July 21 in San Francisco.

Grady previously had to limit the number of new patient visits to its Coumadin clinic per day due to the length of time — nearly 90 minutes — required to help each new patient understand their condition and self-management responsibilities. This could delay the date of the first visit for new patients.

Despite Grady’s heavily underserved, older patient population – which includes many computer novices – 100 percent of patients participate in the interactive multimedia program during their clinic visit. The program educates them about their condition and treatment, and engages them to actively self-manage their care.

Grady Health System is one of the largest public health systems in the United States. Grady consists of the 953-bed Grady Memorial Hospital, six neighborhood health centers, Crestview Health & Rehabilitation Center, and Children's Healthcare of Atlanta at Hughes Spalding, which is operated as a Children's affiliate.

Emmi’s proprietary interactive communication methodology – which incorporates graphics, text and spoken words – delivers actionable health information to patients at key moments across the continuum of care. It has been demonstrated to help healthcare providers reduce costs, increase revenue and improve outcomes by engaging and empowering patients. The platform allows providers to track the delivery and consumption of information to measure the clinical and financial impact of patient engagement and meet regulatory guidelines. The web-based platform requires no installation or maintenance and can be used in stand-alone mode or fully integrated into existing systems.

For more information: www.gradyhealth.org

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init